Expression Analysis of Dopamine Receptor Subtypes in Normal Human Pituitaries, Nonfunctioning Pituitary Adenomas and Somatotropinomas, and the Association between Dopamine and Somatostatin Receptors with Clinical Response to Octreotide-LAR in Acromegaly
AUTOR(ES)
Neto, Leonardo Vieira
FONTE
The Endocrine Society
RESUMO
Context: Dopamine receptor (DR) and somatostatin receptor subtype expression in pituitary adenomas may predict the response to postsurgical therapies.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2730344Documentos Relacionados
- Octreotide-LAR + adrenalectomia bilateral no manejo de tumores carcinóides produtores de ACTH
- Study of major genetic factors involved in pituitary tumorigenesis and their impact on clinical and biological characteristics of sporadic somatotropinomas and non-functioning pituitary adenomas
- ANÁLISE DA EXPRESSÃO DOS RECEPTORES DA SOMATOSTATINA (SST1-5) E DA DOPAMINA (DR2) EM ADENOMAS HIPOFISÁRIOS
- Glycoprotein hormone genes are expressed in clinically nonfunctioning pituitary adenomas.
- Efficacy of cabergoline therapy in patients with non-functioning pituitary adenomas: A single center clinical experience
